The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients

Colorectal cancer is a leading cause of morbidity and mortality worldwide. This study investigates the association between GLP-1 receptor agonists (GLP-1 RAs) and five-year mortality in patients with primary colon cancer, considering BMI. Using data from the University of California Health Data Warehouse, 6,871 patients were analyzed. Five-year mortality was 15.5% for GLP-1 RA users compared to 37.1% for non-users. Analyses showed significantly lower odds of five-year mortality with GLP-1 RA use (OR = 0.38, 95% CI: 0.21-0.64). This benefit persisted after adjusting for confounders, including disease severity, but was found to only extend to high obese patients (BMI > 35) in stratified modeling.